G6PD deficiency and cardiovascular risk: A systematic review
1 Southern University and A&M College USA.
2 Clinic of Propedeutics of Internal Diseases, UMHAT Aleksandrovska, Medical University, Bulgaria.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 20(02), 016–028.
Article DOI: 10.30574/wjbphs.2024.20.2.0832
Publication history:
Received on 18 September 2024; revised on 25 October 2024; accepted on 28 October 2024
Abstract:
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common X-linked enzymatic disorders worldwide, affecting over 400 million individuals. The enzyme G6PD plays a critical role in maintaining cellular redox homeostasis by generating NADPH, which is essential for protecting cells from oxidative stress. Its deficiency leads to reduced antioxidant capacity, particularly in red blood cells, causing hemolysis under oxidative stress. Beyond hemolysis, emerging evidence suggests that G6PD deficiency may have broader systemic effects, including an impact on cardiovascular health. This systematic review aims to explore the association between G6PD deficiency and cardiovascular risk.
Keywords:
Glucose-6-phosphate dehydrogenase (G6PD); Cardiovascular disease; G6PD Deficiency; Hemolysis; Enzymatic Disorders.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0